Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany.
Schäfer R, Dominici M, Müller I, Horwitz E, Asahara T, Bulte JW, Bieback K, Le Blanc K, Bühring HJ, Capogrossi MC, Dazzi F, Gorodetsky R, Henschler R, Handgretinger R, Kajstura J, Kluger PJ, Lange C, Luettichau Iv, Mertsching H, Schrezenmeier H, Sievert KD, Strunk D, Verfaillie C, Northoff H. Schäfer R, et al. Among authors: horwitz e. Cytotherapy. 2009;11(2):245-55. doi: 10.1080/14653240802582117. Cytotherapy. 2009. PMID: 19152153
Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells.
Parwani KK, Branella GM, Burnham RE, Burnham AJ, Bustamante AYS, Foppiani EM, Knight KA, Petrich BG, Horwitz EM, Doering CB, Spencer HT. Parwani KK, et al. Among authors: horwitz em. Front Immunol. 2024 Feb 29;15:1331322. doi: 10.3389/fimmu.2024.1331322. eCollection 2024. Front Immunol. 2024. PMID: 38487542 Free PMC article.
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
Shafat T, Grupel D, Porges T, Abuhasira R, Belkin A, Deri O, Oster Y, Zahran S, Horwitz E, Horowitz NA, Khatib H, Batista MV, Cortez AC, Brosh-Nissimov T, Segman Y, Ishay L, Cohen R, Atamna A, Spallone A, Chemaly RF, Ramos-Ramos JC, Chowers M, Rogozin E, Oren NC, Keske Ş, Barchad OW, Nesher L; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV). Shafat T, et al. Among authors: horwitz e. Cancer Med. 2024 Feb;13(3):e6997. doi: 10.1002/cam4.6997. Cancer Med. 2024. PMID: 38400683 Free PMC article.
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Mak KS, et al. Among authors: horwitz em. Eur Urol Focus. 2024 Feb 1:S2405-4569(24)00011-7. doi: 10.1016/j.euf.2024.01.008. Online ahead of print. Eur Urol Focus. 2024. PMID: 38307806
Metabolites Associated With Uremic Symptoms in Patients With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Wulczyn KE, Shafi T, Anderson A, Rincon-Choles H, Clish CB, Denburg M, Feldman HI, He J, Hsu CY, Kelly T, Kimmel PL, Mehta R, Nelson RG, Ramachandran V, Ricardo A, Shah VO, Srivastava A, Xie D, Rhee EP, Kalim S; CRIC Study Investigators. Wulczyn KE, et al. Am J Kidney Dis. 2024 Jan 23:S0272-6386(24)00044-1. doi: 10.1053/j.ajkd.2023.11.013. Online ahead of print. Am J Kidney Dis. 2024. PMID: 38266973
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, Ciceri F, Ruggeri A, Snowden J, Heslop HE, Mackall CL, June CH, Sureda AM, Perales MA. Levine BL, et al. Among authors: horwitz em. Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w. Nat Med. 2024. PMID: 38195751 No abstract available.
A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
Lukez A, Handorf E, Mendenhall NP, Henderson RH, Stish BJ, Davis BJ, Hallman M, Horwitz EM, Vapiwala N, Wong JK. Lukez A, et al. Among authors: horwitz em. Prostate. 2024 Mar;84(4):395-402. doi: 10.1002/pros.24660. Epub 2023 Dec 18. Prostate. 2024. PMID: 38108113
561 results